Siemens Healthineers : Q4/FY earnings due on 9 November – focus on FY 2022-23 guidance
>FY 2021-22 set to be in line with guidance - For FY 2021-22, we have slightly lifted our forecast by 1% for adj. EBIT and adj. EPS on a better product mix in Diagnostics; we estimate sales of € 21.6bn (+20% y-o-y; 6.4% y-o-y comparable), an adj. EBIT of € 3.57bn (16.5% margin; +14% y-o-y) and adj. EPS of € 2.25 (+11% y-o-y). We are in the middle to low end of the guidance range (5.5-7.5% y-o-y comparable sales growth; adj. EPS of € 2.25-2.35). Looking at Q4 specifica...Siemens Healthineers AG is a Germany-based company that supplies technology to the healthcare industry. The Company offers a wide range of products and services in the fields of diagnostic and therapeutic imaging, laboratory and point of care diagnostics, and molecular medicine. It provides medical technology and software solutions, as well as clinical consulting services. Additionally, the Company is developing its digital health and enterprise services trough expanding precision medicine, transforming care delivery, improving patient experience, and digitalizing healthcare to enable healthcare providers to increase value. Siemens AG is a majority shareholder of the Company. The Company is active worldwide.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.